Theresa D Feola1, Cynthia A Bonville2, Donald A Cibula3, Sherly Jose4, Geetha Nattanmai4, Joseph B Domachowske2, Manika Suryadevara2. 1. a Division of Infectious Diseases, Department of Medicine, SUNY Upstate Medical University , Syracuse , NY , USA. 2. b Division of Infectious Diseases, Department of Pediatrics, SUNY Upstate Medical University , Syracuse , NY , USA. 3. c Department of Public Health and Preventive Medicine , SUNY Upstate Medical University , Syracuse , NY , USA. 4. d Division of Infectious Diseases, New York State , Department of Health , Albany , NY.
Abstract
BACKGROUND: Nasopharyngeal pneumococcal carriage rates among HIV-infected adults has not been described since conjugate pneumococcal vaccine-13 (PCV13) was added to the universal infant and childhood vaccination schedule in 2010. METHODS: HIV-infected adults presenting for routine health care visits to the Designated AIDS Center in Syracuse, NY between December 2013 and June 2015 were eligible for enrollment. Demographic, medical, and social history were recorded after obtaining informed consent. Nasopharyngeal samples were collected and cultured for the presence of Streptococcus pneumoniae using standard microbiologic techniques. Antibiotic susceptibility testing was performed using E-test→. RESULTS: 707 nasopharyngeal samples were collected from 414 HIV-infected adults. 18 samples were culture positive for S. pneumoniae; 1 (6%) isolate was of vaccine-type, 9 (50%) were non-vaccine types, and 8 (44%) were non-typeable. The 18 isolates were recovered from 15 different patients (4% of those enrolled). Three patients were culture positive for pneumococcus isolated from 2 consecutive samples, with non-typeable pneumococci identified consecutively from 2 patients and serotype 35B identified consecutively from 1 patient. The most commonly identified non-vaccine serotypes were 35B and 15B/C. Identified pneumococci were penicillin and cefotaxime susceptible. CONCLUSION: Four percent of HIV-infected adults in our study population were colonized with S. pneumoniae. The non-vaccine serotypes 35B and 15B/C predominated.
BACKGROUND: Nasopharyngeal pneumococcal carriage rates among HIV-infected adults has not been described since conjugate pneumococcal vaccine-13 (PCV13) was added to the universal infant and childhood vaccination schedule in 2010. METHODS:HIV-infected adults presenting for routine health care visits to the Designated AIDS Center in Syracuse, NY between December 2013 and June 2015 were eligible for enrollment. Demographic, medical, and social history were recorded after obtaining informed consent. Nasopharyngeal samples were collected and cultured for the presence of Streptococcus pneumoniae using standard microbiologic techniques. Antibiotic susceptibility testing was performed using E-test→. RESULTS: 707 nasopharyngeal samples were collected from 414 HIV-infected adults. 18 samples were culture positive for S. pneumoniae; 1 (6%) isolate was of vaccine-type, 9 (50%) were non-vaccine types, and 8 (44%) were non-typeable. The 18 isolates were recovered from 15 different patients (4% of those enrolled). Three patients were culture positive for pneumococcus isolated from 2 consecutive samples, with non-typeable pneumococci identified consecutively from 2 patients and serotype 35B identified consecutively from 1 patient. The most commonly identified non-vaccine serotypes were 35B and 15B/C. Identified pneumococci were penicillin and cefotaxime susceptible. CONCLUSION: Four percent of HIV-infected adults in our study population were colonized with S. pneumoniae. The non-vaccine serotypes 35B and 15B/C predominated.
Authors: Andrea C Farnham; Christopher M Zimmerman; Vikki Papadouka; Kevin J Konty; Jane R Zucker; Geetha V Nattanmai; Sherly Jose; Jennifer B Rosen Journal: JAMA Pediatr Date: 2015-07 Impact factor: 16.193
Authors: Jennifer B Rosen; Ann R Thomas; Catherine A Lexau; Art Reingold; Jim L Hadler; Lee H Harrison; Nancy M Bennett; William Schaffner; Monica M Farley; Bernard W Beall; Matt R Moore Journal: Clin Infect Dis Date: 2011-07-15 Impact factor: 9.079
Authors: Ron Dagan; Christine Juergens; James Trammel; Scott Patterson; David Greenberg; Noga Givon-Lavi; Nurith Porat; Alejandra Gurtman; William C Gruber; Daniel A Scott Journal: J Infect Dis Date: 2014-10-29 Impact factor: 5.226
Authors: Queralt Jordano; Vicenç Falcó; Benito Almirante; Ana María Planes; Oscar del Valle; Esteve Ribera; Oscar Len; Carles Pigrau; Albert Pahissa Journal: Clin Infect Dis Date: 2004-05-12 Impact factor: 9.079
Authors: J Burgos; V Falcó; A Borrego; R Sordé; M N Larrosa; X Martinez; A M Planes; A Sánchez; M Palomar; J Rello; A Pahissa Journal: Clin Microbiol Infect Date: 2012-05-14 Impact factor: 8.067
Authors: Stefan Flasche; Albert Jan Van Hoek; Elizabeth Sheasby; Pauline Waight; Nick Andrews; Carmen Sheppard; Robert George; Elizabeth Miller Journal: PLoS Med Date: 2011-04-05 Impact factor: 11.069